JAN - JanOne Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1500
0.0000 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.1500
Open3.4000
Bid0.0000 x 1200
Ask3.3000 x 1800
Day's Range3.0673 - 3.4000
52 Week Range2.0000 - 9.5600
Volume73,758
Avg. Volume278,406
Market Cap6.041M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Amol Soin, MD, One Of The Nation's Leading Pain Experts, Named As JanOne's Chief Medical Officer
    PR Newswire

    Amol Soin, MD, One Of The Nation's Leading Pain Experts, Named As JanOne's Chief Medical Officer

    JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced the addition of Amol Soin, MD as the company's chief medical officer. Dr. Soin has been recognized multiple times as one of America's Top Doctors and is the recipient of the Patient's Choice Award, an honor given only to the top 1% of physicians in the country.

  • JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week
    PR Newswire

    JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week

    JanOne Inc. (NASDAQ:JAN) Scientific Advisory Board Chair, Dr. Christopher Kevil sat down with Eric Bolling, JanOne's President and Chairman and host of America This Week, to discuss the effects of the company's lead drug candidate, TV1001SR, for the treatment of peripheral artery disease (PAD) and associated pain. Dr. Kevil was joined by renowned pain expert, Dr. Amol Soin, and both provided their insights and perspective for an approach that treats the mechanisms of a disease process, such as in PAD, and concurrently can have significant pain relieving qualities. Of particular interest was how in prior studies TV1001SR was able to treat both the underlying condition and the associated pain with no addictive repercussions. The company believes that this could mitigate the need for prescription opioids that often come with a risk for addiction, when patients are suffering from severe pain.

  • Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
    PR Newswire

    Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board

    JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will chair the Company's scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD. Dr. Kevil is considered a foremost expert in the development and analysis of various small molecules, biologics, disease indications, pharmaceutical, medical device, and drug delivery systems.

  • PR Newswire

    JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer

    JanOne Inc. (NASDAQ:JAN) a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced the hiring of Tony Giordano, Ph.D. to serve as its Chief Scientific Officer.

  • PR Newswire

    JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)

    JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, today announced a licensing agreement for TV1001SR, a treatment for Peripheral Artery Disease, commonly called PAD. The agreement with LSU Health Shreveport, UAB Research Foundation, and TheraVasc, Inc., gives JanOne a worldwide, exclusive license for TV1001SR along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite.

  • JanOne Names America This Week Host And Financial Commentator Eric Bolling As President And Chairman
    PR Newswire

    JanOne Names America This Week Host And Financial Commentator Eric Bolling As President And Chairman

    LAS VEGAS, Sept. 12, 2019 /PRNewswire/ -- JanOne, Inc. (NASDAQ: JAN), a newly launched initiative with the focused intent of offering innovative, actionable solutions to end the opioid crisis, is proud to name host of America This Week and financial commentator Eric Bolling as its President and Chairman. As one personally affected by the opioid scourge, Bolling has dedicated himself to fighting the opioid epidemic by executing the mission of JanOne: To help to end the opioid crisis by, among other things, developing revolutionary pain medications to replace today's highly addictive and often fatal opioids. "I am elated to become part of JanOne and to help fulfill the mission of developing alternative, non-opioid pain drugs," Bolling said.

  • PR Newswire

    ARCA Now Doing Business as JanOne, Trades Under New Nasdaq Ticker Symbol JAN

    LAS VEGAS, Sept. 11, 2019 /PRNewswire/ -- Appliance Recycling Centers of America, Inc. (NASDAQ: JAN) today announced that, on September 10, 2019, the company has been renamed JanOne Inc. and, effective this morning, now trades under the ticker symbol JAN, with a new CUSIP number (47089W 104). The company's new name, JanOne, expresses the start of a new day in the fight against the opioid epidemic. January One is the first day of a New Year – a day of optimism, resolution, and hope.  JanOne affirms the company's strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation's history.